# EDGAR Filing Document

**Accession Number:** 0001934064
**File Stem:** 0001104659-23-027340
**Filing Date:** 2023-3
**Character Count:** 7882
**Document Hash:** 1b23c9a1f7ab3dde16c6054a0d40c464
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-027340.hdr.sgml**: 20230301

**ACCESSION NUMBER**: 0001104659-23-027340

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230301

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230301

**DATE AS OF CHANGE**: 20230301

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ProSomnus, Inc.
- **CENTRAL INDEX KEY:** 0001934064
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41567
- **FILM NUMBER:** 23694016

**BUSINESS ADDRESS:**
- **STREET 1:** 5675 GIBRALTAR AVENUE
- **CITY:** PLEASANTON
- **STATE:** CA
- **ZIP:** 94588
- **BUSINESS PHONE:** 844-537-5337

**MAIL ADDRESS:**
- **STREET 1:** 5675 GIBRALTAR AVENUE
- **CITY:** PLEASANTON
- **STATE:** CA
- **ZIP:** 94588

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LAAA Merger Corp.
- **DATE OF NAME CHANGE:** 20220615

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE<br> SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **March 1, 2023**

**PROSOMNUS, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41567** | **88-2978216** |
| (State or other jurisdiction <br> of incorporation) | (Commission File Number) | (IRS Employer <br> Identification No.) |

---

---

| | |
|:---|:---|
| **5675 Gibraltar Avenue**<br> **Pleasanton, California** | **94588** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(844) 537-5337** 

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on<br> which registered** |
| Common Stock, par value $0.0001 per share | OSA | The Nasdaq Stock Market LLC |
| Warrants, each whole warrant exercisable for one share of Common Stock for $11.50 per share | OSAAW | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 7.01. Regulation FD Disclosure.**

On March 1, 2023, ProSomnus, Inc. (the "Company") issued a press release announcing the Company's participation in two upcoming investor conferences.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [99.1](tm238097d2_ex99-1.htm) | [Press Release, dated March 1, 2023](tm238097d2_ex99-1.htm) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ProSomnus, Inc.** | **ProSomnus, Inc.** |
|  | By: | /s/ Len Liptak |
|  |  | Name: Len Liptak |
|  |  | Title: Chief Executive Officer |
| Dated: March 1, 2023 |  |  |

---

## Exhibit 99.1

**Exhibit 99.1**

**ProSomnus to Present at Two Upcoming Investor Conferences in March 2023**

SAN FRANCISCO, March 1, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. ("the Company") (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announces that Company management will participate in two investor conferences in the month of March 2023:

&nbsp;&nbsp;&nbsp;&nbsp;· 35<sup>th</sup> Annual Roth Conference on March 12-14, 2023

&nbsp;&nbsp;&nbsp;&nbsp;· 33<sup>rd</sup> Annual Oppenheimer Healthcare Conference on March 13-15, 2023

**About 35<sup>th</sup> Annual Roth Conference**

ProSomnus' Chief Executive Officer, Len Liptak, and Executive Chair, Laing Rikkers, will engage in a fireside chat during the Roth Annual Conference, which will be held at the Ritz Carlton, Laguna Niguel on March 12-14, 2023.

The fireside chat is scheduled for Monday, March 13 at 3:30 pm Pacific Time / 6:30 pm Eastern Time and will be accessible via a live webcast <u>here</u>. A replay of discussion will be available after the conclusion of the live discussion on the Investor Relations section of the Company's website.

**About 33<sup>rd</sup> Annual Oppenheimer Healthcare Conference**

ProSomnus' Chief Executive Officer, Len Liptak, and Executive Chair, Laing Rikkers, will deliver a presentation during the Oppenheimer Annual Healthcare Conference, which will be held virtually on March 13-15, 2023.

The presentation is scheduled on Tuesday, March 14 at 1:40 pm Pacific Time / 4:40 pm Eastern Time and will be accessible via a live webcast <u>here</u>. A replay of presentation will be available after the conclusion of the live presentation on the Investor Relations section of the Company's website.

**About ProSomnus**

ProSomnus (NASDAQ: OSA) precision intraoral medical devices offer effective, economical, and patient preferred treatment for patients suffering from Obstructive Sleep Apnea. ProSomnus is the first manufacturer of mass-customized Precision Oral Appliance Therapy (OAT) devices to treat OSA, which affects over 74 million people in North America and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus's patented, FDA-cleared devices are a less invasive and more comfortable alternative to Continuous Positive Airway Pressure (CPAP) therapy, and lead to more effective and patient-preferred outcomes. A growing body of research, including studies published by the *Journal of Clinical Sleep Medicine* and *Military Medicine*, suggests ProSomnus's Precision OAT devices are an effective treatment for mild to moderate OSA. Additional clinical research has shown that ProSomnus's Precision OAT devices mitigate many of the side effects associated with alternative treatments and improve economics for payers and providers. With more than 187,500 devices delivered, ProSomnus's devices are the most prescribed Precision OAT in the U.S. ProSomnus's FDA-cleared devices are authorized by the Department of Defense and the U.S. Army, and are often covered by medical insurance, Medicare, and social health programs in key international markets. To learn more, visit <u>www.ProSomnus.com</u>.

**Investor Contact**<br> Mike Cavanaugh<br> ICR Westwicke<br> Phone: +1.617.877.9641<br> Email: Mike.Cavanaugh@westwicke.com

**Media Contact**<br> Kyle Evans<br> ICR Westwicke<br> Phone: +1.646.277.1295<br> Email: Kyle.Evans@westwicke.com